Rhea-AI Summary
Azora Therapeutics (Nasdaq: AZR) has established a five-member board of directors with experience in drug development, public-company governance, gastroenterology and immunology. The board comprises CEO and co-founder Matt Davidson and four independent directors: Wendy Young, Aida Habtezion, Thomas Soloway and Paul J. Hastings.
Young previously headed Small Molecule Drug Discovery at Genentech, while Habtezion served as Pfizer’s Chief Medical Officer and Head of Worldwide Medical & Safety. Soloway is CEO of T-knife Therapeutics, and Hastings is CEO of Nkarta. Azora expects the board to support its strategy to advance AT177 into clinical development and through proof of concept for ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Azora Therapeutics (AZR)?
Azora Therapeutics (AZR) last closed at $3.71.
What is the market cap of Azora Therapeutics (AZR)?
The market cap of Azora Therapeutics (AZR) is approximately $9.7M.